Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
10 studies found for:    GVHD, John Koreth
Show Display Options
Rank Status Study
1 Recruiting Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Conditions: Chronic Graft Versus Host Disease;   Chronic GVHD;   Complications of Organ Transplant Stem Cells
Interventions: Other: Treg-enriched infusion;   Drug: Interleukin-2
2 Recruiting A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease
Condition: Chronic Graft-versus-host-disease
Interventions: Procedure: Extracorporeal Photopheresis (ECP);   Drug: Interleukin-2
3 Completed
Has Results
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Condition: Hematologic Malignancies
Interventions: Drug: Bortezomib (Velcade);   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: blood stem cell transplantation
4 Completed
Has Results
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Conditions: Leukemia;   Lymphoma;   Myelodysplastic Syndrome
Intervention: Drug: Bortezomib, Tacrolimus, Methotrexate
5 Active, not recruiting Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
Condition: Graft Versus Host Disease
Interventions: Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Bortezomib;   Drug: Sirolimus
6 Active, not recruiting
Has Results
Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
Condition: Graft Versus Host Disease
Intervention: Drug: Interleukin-2
7 Recruiting Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic Graft-versus-Host-Disease
Condition: Chronic Versus Graft Host Disease
Intervention: Drug: Interleukin-2
8 Active, not recruiting
Has Results
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Condition: Chronic Graft-versus-host Disease
Intervention: Drug: Interleukin-2
9 Completed
Has Results
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
Condition: Chronic Graft Versus Host Disease
Interventions: Drug: bortezomib;   Drug: Prednisone
10 Recruiting Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
Condition: Multiple Myeloma
Interventions: Procedure: Allogeneic HSCT;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Bortezomib;   Drug: Ixazomib;   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.